{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T20:05:11Z","timestamp":1790107511034,"version":"4.0.1"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":7,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Patients with prostate cancer (PC) frequently receive multiple medications for comorbidities, increasing the risk of drug\u2013drug interactions (DDIs). Despite guidelines highlighting DDI relevance, data on real-world management are limited. This international survey aimed to characterize current practices, barriers, and needs in this setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>A self-administered, multiple-choice online survey was sent to 3342 Italian oncologists (AIOM\/Meet-URO members) and 19 139 global healthcare professionals via the ONCOassist app. A part of the survey included optional case studios completed only by Italian respondents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Responses were received by 69 healthcare professionals in Italy and 1064 worldwide. Overall, DDIs were widely recognized as clinically relevant in PC care. Digital tools (online databases and smartphone applications) were the most frequently used resources for DDI assessment in both cohorts, whereas AI-based tools were limited. Italian oncologists reported limited on-site pharmacologist access (29%), while global respondents reported more frequent pharmacologist support (76%). Common barriers included time constraints, uncertain reliability of sources, and lack of training. When DDI checkers conflicted, Italian and global respondents favored pharmacologist consultation, although global users relied also on literature (31%) and clinical judgment (26%). Proposed solutions differed between cohorts: Italian clinicians emphasized the need for greater access to pharmacologists\u2019 support, whereas the global cohort highlighted institutional training and educational initiatives. Clinical scenarios demonstrated awareness of specific DDI risks, with cautious selection of ARTAs and co-medications in line with current recommendations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Although limited by potential selection bias and restricted generalizability, these findings suggest that strengthening multidisciplinary collaboration could enhance patient safety and optimize therapy outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag360","type":"journal-article","created":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T12:07:18Z","timestamp":1789474038000},"source":"Crossref","is-referenced-by-count":0,"title":["Global management of drug\u2013drug interaction in patients with prostate cancer: international survey by Meet-URO group and ONCOassist"],"prefix":"10.1093","volume":"31","author":[{"given":"Anna Amela","family":"Valsecchi","sequence":"first","affiliation":[{"name":"Department of Oncology, University of Turin, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Ospedale Molinette, 10126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7877-8988","authenticated-orcid":false,"given":"Michele","family":"Maffezzoli","sequence":"additional","affiliation":[{"name":"Oncology Unit, University Hospital of Parma, Parma, 43126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Cursano","sequence":"additional","affiliation":[{"name":"Department of Oncology, Ospedale Ca\u2019 Foncello, Treviso, 31100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Di Civita","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome, 00161,","place":["Italy"]},{"name":"Department of Medical Oncology, Medical Oncology Unit, Sandro Pertini Hospital , Rome, 00157,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fiorenza","family":"Santamaria","sequence":"additional","affiliation":[{"name":"Department of Experimental Medicine, Sapienza University of Rome , Rome, 00161,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Kingspergher","sequence":"additional","affiliation":[{"name":"Ospedale San Maurizio , Bolzano, 39100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3252-4226","authenticated-orcid":false,"given":"Elisa","family":"Zanardi","sequence":"additional","affiliation":[{"name":"UO Clinica di Oncologia Medica, IRCCS Azienda Ospedaliera Metropolitana , Genoa, 16132,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Procopio","sequence":"additional","affiliation":[{"name":"Department of Oncology, Genitourinary Medical Oncology, Fondazione IRCCS Istituto Nazionale Tumori Milano , Milan, 20133,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suleka","family":"Ashok","sequence":"additional","affiliation":[{"name":"ONCOassist , V93 T8K7,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lakshmi","family":"Ramachandran","sequence":"additional","affiliation":[{"name":"ONCOassist , V93 T8K7,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renita","family":"George","sequence":"additional","affiliation":[{"name":"ONCOassist , V93 T8K7,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Bambury","sequence":"additional","affiliation":[{"name":"ONCOassist , V93 T8K7,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Bambury","sequence":"additional","affiliation":[{"name":"ONCOassist , V93 T8K7,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eoin","family":"O\u2019Carroll","sequence":"additional","affiliation":[{"name":"ONCOassist , V93 T8K7,","place":["Ireland"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0764-3650","authenticated-orcid":false,"given":"Giuseppe Luigi","family":"Banna","sequence":"additional","affiliation":[{"name":"Portsmouth Hospitals University NHS Trust , Portsmouth, PO6 3LY,","place":["United Kingdom"]},{"name":"Faculty of Science and Health, School of Pharmacy and Biomedical Sciences, University of Portsmouth , Portsmouth, PO1 2UP,","place":["United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8906-3785","authenticated-orcid":false,"given":"Massimo","family":"Di Maio","sequence":"additional","affiliation":[{"name":"Department of Oncology, University of Turin, A.O.U. Citt\u00e0 della Salute e della Scienza di Torino, Ospedale Molinette, 10126,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Santini","sequence":"additional","affiliation":[{"name":"Department of Sciences and Medical-Surgery Biotechnologies, La Sapienza, Universit\u00e0 di Roma , Rome, 04100,","place":["Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"2026092215220145800_oyag360-B1","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.acuro.2020.06.009","article-title":"Treatment for castration-resistant prostate cancer and drug interaction risk in polymedicated patients [Tratamiento del c\u00e1ncer de pr\u00f3stata resistente a la castraci\u00f3n y riesgo de interacciones farmacol\u00f3gicas en pacientes polimedicados]","volume":"44","author":"Ju\u00e1rez Soto","year":"2020","journal-title":"Actas Urol Esp (Engl Ed)"},{"key":"2026092215220145800_oyag360-B2","doi-asserted-by":"publisher","first-page":"105119","DOI":"10.1016\/j.esmoop.2025.105119","article-title":"Clinical relevance and methodological approach for the assessment of drug-drug interactions in cancer patients: a position statement from the Italian Association of Medical Oncology (AIOM) and the Italian Society of Pharmacology (SIF)","volume":"10","author":"Del Re","year":"2025","journal-title":"ESMO Open"},{"key":"2026092215220145800_oyag360-B3","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1177\/10781552241238198","article-title":"Review of drug-drug interactions in patients with prostate cancer","volume":"30","author":"Ruplin","year":"2024","journal-title":"J Oncol Pharm Pract"},{"key":"2026092215220145800_oyag360-B4","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1007\/s00280-017-3291-z","article-title":"Potential drug-drug interactions with abiraterone in metastatic castration-resistant prostate cancer patients: a prevalence study in France","volume":"79","author":"Bonnet","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"2026092215220145800_oyag360-B5","doi-asserted-by":"publisher","first-page":"103736","DOI":"10.1016\/j.esmoop.2024.103736","article-title":"Androgen receptor pathway inhibitors and drug-drug interactions in prostate cancer","volume":"9","author":"Bolek","year":"2024","journal-title":"ESMO Open"},{"key":"2026092215220145800_oyag360-B6","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1080\/17425255.2024.2353749","article-title":"New-generation androgen receptor signaling inhibitors (ARSIs) in metastatic hormone-sensitive prostate cancer (mHSPC): pharmacokinetics, drug-drug interactions (DDIs), and clinical impact","volume":"20","author":"Gasperoni","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026092215220145800_oyag360-B7","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.ctrv.2017.03.001","article-title":"The role of drug-drug interactions in prostate cancer treatment: Focus on abiraterone acetate\/prednisone and enzalutamide","volume":"55","author":"Del Re","year":"2017","journal-title":"Cancer Treat Rev"},{"key":"2026092215220145800_oyag360-B8","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1007\/s00228-016-2120-3","article-title":"High prevalence of potential drug-drug interactions in patients with castration-resistant prostate cancer treated with abiraterone acetate","volume":"72","author":"Jamani","year":"2016","journal-title":"Eur J Clin Pharmacol"},{"key":"2026092215220145800_oyag360-B9","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1080\/14737140.2024.2328778","article-title":"Drug-drug interaction potential among patients with nonmetastatic castration-resistant prostate cancer (nmCRPC) treated with novel androgen receptor inhibitors","volume":"24","author":"Appukkuttan","year":"2024","journal-title":"Expert Rev Anticancer Ther"},{"key":"2026092215220145800_oyag360-B10","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1007\/s11523-019-00674-0","article-title":"Evaluation of clinically relevant drug-drug interactions and population pharmacokinetics of darolutamide in patients with nonmetastatic castration-resistant prostate cancer: results of pre-specified and post hoc analyses of the phase III ARAMIS trial","volume":"14","author":"Shore","year":"2019","journal-title":"Target Oncol"},{"key":"2026092215220145800_oyag360-B11","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s10557-023-07453-0","article-title":"Pharmacokinetic interactions between abiraterone, apalutamide, darolutamide or enzalutamide and antithrombotic drugs: prediction of clinical events and review of pharmacological information","volume":"38","author":"Boujonnier","year":"2024","journal-title":"Cardiovasc Drugs Ther"},{"key":"2026092215220145800_oyag360-B12","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16193336","article-title":"Drug interactions between androgen receptor axis-targeted therapies and antithrombotic therapies in prostate cancer: Delphi consensus","volume":"16","author":"Leblanc","year":"2024","journal-title":"Cancers (Basel)"},{"key":"2026092215220145800_oyag360-B13","doi-asserted-by":"publisher","first-page":"e2419851","DOI":"10.1001\/jamanetworkopen.2024.19851","article-title":"Agreement of different drug-drug interaction checkers for proton pump inhibitors","volume":"7","author":"Carollo","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026092215220145800_oyag360-B14","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1080\/17425255.2024.2322134","article-title":"Exploring the level of agreement among different drug-drug interaction checkers: a comparative study on direct oral anticoagulants","volume":"20","author":"Carollo","year":"2024","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"2026092215220145800_oyag360-B15","author":"Meet-Uro 34 -"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag360\/71123120\/oyag360.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag360\/71123120\/oyag360.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/10\/oyag360\/71123120\/oyag360.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:22:08Z","timestamp":1790104928000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag360\/8802114"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,9]]},"references-count":15,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,9]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag360","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,9]]},"article-number":"oyag360"}}